Biotechnology - Clinical Stage GPCR Drug Discovery
Strategic Profile
The company has a global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Analyst sentiment remains bullish with eight buy ratings and no hold or sell ratings, with an average target price of $33.86 indicating potential upside of 11.81% from current levels.
Cyborg Score Rationale
Septerna has strong financial runway with $561.6M in cash, equivalents, and marketable securities including a $195M Novo Nordisk upfront payment, with expected runway into at least 2029. Recent positive Phase 1 results for SEP-631 support advancement into Phase 2 development for chronic spontaneous urticaria. However, the company shows a negative forward P/E of -30.31 and negative EPS of -6.90, reflecting continued development stage losses.
Top Insights
Positive Phase 1 data for SEP-631 (MRGPRX2 NAM) supports planned Phase 2b trial in chronic spontaneous urticaria with expansion into broader mast cell disease indications (March 2026)
SEP-479 selected as next-generation oral PTH1R agonist for hypoparathyroidism with Phase 1 trial planned in H1 2026
Novo Nordisk partnership validates platform with $195M upfront plus over $2.2B in potential milestone payments
Pipeline includes promising programs: PTH1R for hypoparathyroidism, SEP-631 for chronic spontaneous urticaria, and TSHR Program for Graves' disease and thyroid eye disease
Named Competitors
GPCR Therapeutics Platform — Clinical-stage GPCR drug discovery
Metabolic Disease Solutions — GLP-1 and obesity/metabolic disorder focus
Allergy/Immunology Programs — Mast cell and immunology indications
Thyroid Disease Platform — Metabolic and endocrine disease focus
Recent Developments
(March 2026) Positive Phase 1 data for SEP-631 announced with Phase 2b CSU trial planned
(February 2026) CEO presentation at TD Cowen Healthcare Conference (March 3, 2026)
(November 2025) Q3 2025 results showing $561.6M cash position and SEP-479 advancement
(February 2026) Chief Legal Officer stock option grant issued at $25.41 exercise price
Open the full interactive Septerna, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.